New drug trial aims to clear hepatitis b in people with HIV

NCT ID NCT06497504

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

Summary

This study is testing whether an experimental drug called bepirovirsen can help people who have both HIV and chronic hepatitis B. Researchers want to see if the treatment can clear detectable hepatitis B virus from the blood while participants continue their regular HIV medications. The trial involves 157 adults whose HIV is well-controlled and who meet specific hepatitis B levels.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Bakersfield, California, 93301, United States
GSK Investigational Site

San Francisco, California, 94115, United States
GSK Investigational Site

Orlando, Florida, 32803, United States
GSK Investigational Site

West Palm Beach, Florida, 33409, United States
GSK Investigational Site

Baltimore, Maryland, 21287, United States
GSK Investigational Site

Minneapolis, Minnesota, 55415, United States
GSK Investigational Site

Hillsborough, New Jersey, 08844, United States
GSK Investigational Site

Almagro, C1427CEA, Argentina
GSK Investigational Site

Buenos Aires, 1023, Argentina
GSK Investigational Site

Buenos Aires, C1181ACI, Argentina
GSK Investigational Site

Buenos Aires, C1425AGC, Argentina
GSK Investigational Site

La Plata, B1900AVG, Argentina
GSK Investigational Site

Rosario, S2002KDR, Argentina
GSK Investigational Site

Aracaju, 49060-010, Brazil
GSK Investigational Site

Campinas, 13034-685, Brazil
GSK Investigational Site

Curitiba, 80810-050, Brazil
GSK Investigational Site

Manaus, 69040-000, Brazil
GSK Investigational Site

Salvador, 40110-060, Brazil
GSK Investigational Site

São Paulo, 04121-000, Brazil
GSK Investigational Site

Ottawa, Ontario, K1H 8L6, Canada
GSK Investigational Site

Toronto, Ontario, M5G 1K2, Canada
GSK Investigational Site

Montreal, Quebec, H2L 4P9, Canada
GSK Investigational Site

Montreal, Quebec, H4A 3J1, Canada
GSK Investigational Site

Québec, Quebec, G1V 4G2, Canada
GSK Investigational Site

Marseille, 13003, France
GSK Investigational Site

Melun, 77000, France
GSK Investigational Site

Montpellier, 34295, France
GSK Investigational Site

Nantes, 44093, France
GSK Investigational Site

Paris, 75012, France
GSK Investigational Site

Paris, 75018, France
GSK Investigational Site

Genova, 16132, Italy
GSK Investigational Site

Milan, 20157, Italy
GSK Investigational Site

Milan, 20162, Italy
GSK Investigational Site

Naples, 80131, Italy
GSK Investigational Site

Roma, 00153, Italy
GSK Investigational Site

Sassari, 07100, Italy
GSK Investigational Site

Durban, 4052, South Africa
GSK Investigational Site

Johannesburg, 2092, South Africa
GSK Investigational Site

Reiger Park, 1459, South Africa
GSK Investigational Site

Barcelona, 08036, Spain
GSK Investigational Site

Córdoba, 14004, Spain
GSK Investigational Site

Madrid, 28032, Spain
GSK Investigational Site

Madrid, 28040, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

Madrid, 28046, Spain
GSK Investigational Site

Banchiau Taipei, 220, Taiwan
GSK Investigational Site

Kaohsiung City, 813, Taiwan
GSK Investigational Site

Bristol Avon, BS10 5NB, United Kingdom
GSK Investigational Site

London, E1 1BB, United Kingdom
GSK Investigational Site

London, NW3 2QG, United Kingdom
GSK Investigational Site

London, SE5 9RS, United Kingdom

Conditions

Explore the condition pages connected to this study.

HEPATITIS B